• Large real-world study finds new GLP-1 drugs help protect the heart in people with cardiovascular risk.
• Clear evidence shows these medications support heart health beyond their weight-loss effects.
• Semaglutide (Ozempic) and tirzepatide (Mounjaro) offer similar levels of heart protection, with only small differences in results.

GLP-1 Drugs Linked to Better Heart Health

Injectable medications used for weight loss may also lower the risk of major cardiovascular problems in people with type 2 diabetes. Researchers from the Technical University of Munich (TUM) and Harvard Medical School reached this conclusion after analyzing insurance claims data. Their findings show that semaglutide and tirzepatide (sold as Ozempic and Mounjaro) can reduce the risk of serious heart-related events by as much as 18 percent.

The research, published in Nature Medicine, drew on a vast collection of data from U.S. health insurance records. "Those data are collected in routine clinical care and can be used for research. They allow us to answer a broad range of relevant questions efficiently. Importantly, we are studying patients who reflect everyday clinical practice -- unlike the highly selected participants typically enrolled in randomized trials," explains Dr. Nils Krüger, the study's lead author and a physician at the Department of Cardiovascular Diseases at the TUM University Hospital German Heart Center.

Heart Protection Beyond Weight Loss

The results clearly indicate that these newer diabetes treatments help protect the heart in people with elevated cardiovascular risk. Compared with sitagliptin, a diabetes medication known to provide no measurable heart benefits, semaglutide cut the risk of stroke and heart attack by 18 percent. Tirzepatide lowered the combined risk of stroke, heart attack, and death by 13 percent compared with dulaglutide, an older GLP-1 drug already in use.

"Both substances have a cardioprotective effect. Our data show that the benefits emerge from early on, indicating that the effect goes beyond weight loss alone," says Dr. Krüger. However, researchers note that the biological mechanisms behind this protective effect remain uncertain.

Because semaglutide and tirzepatide are relatively new, studies directly examining their cardiovascular effects have been limited, especially those comparing the two drugs head-to-head. The research team from TUM, Harvard Medical School, and Brigham and Women's Hospital aimed to fill this knowledge gap to guide better treatment decisions for patients at risk of heart disease.

Comparing Ozempic and Mounjaro

"According to the manufacturers' claims, each one suggests its own product is more effective than the competitor's at reducing cardiovascular risk," says Prof. Heribert Schunkert, Director of the Department of Cardiovascular Diseases at TUM University Hospital. "Our study, however, shows only small differences in heart outcomes between tirzepatide and semaglutide in the risk groups we analyzed."

Dr. Krüger adds: "We hope our findings will provide clarity to physicians about how these new medications perform in clinical practice. Our transparent study design is also intended to support open scientific discussion about whether and how modern GLP-1 drugs should become part of the standard therapeutic repertoire in cardiovascular medicine."

Recently, Dr. Krüger's team was able to show that treatment with semaglutide or tirzepatide can reduce health risks for people with heart failure with preserved ejection fraction by over 40 percent. The study has been published in the journal JAMA (PMID: 40886075).

This work was funded by the National Institutes of Health (R01-HL141505, R01-AR080194) and the German Heart Foundation (S/02/24, SRF-HF/24, RWE/11/25).

• Heart disease remains the world's top killer, claiming more lives each year than any other condition.
• Scientists are uncovering how gut microbes may influence coronary artery disease (CAD), one of the most common and serious forms of heart disease.
• A research team in Seoul has identified 15 specific bacterial species connected to CAD, offering new insight into how the gut and heart interact.
• Their analysis reveals several biological pathways tied to disease severity, including heightened inflammation and disruptions in metabolism that may worsen heart health.

Cardiovascular diseases claim nearly 20 million lives each year, making them the leading cause of death worldwide. While genetics and lifestyle factors clearly affect a person's heart health, scientists are discovering that microorganisms living in the gut may also have an important influence. These microbes appear to be deeply involved in the development of coronary artery disease (CAD), though their exact roles have long been unclear.

Recent research suggests that the gut microbiome may promote CAD through a variety of biological pathways, influencing inflammation and metabolism in ways that impact the arteries. However, which specific bacteria are responsible -- and how they contribute to disease progression -- has remained uncertain.

Mapping Microbes in Coronary Artery Disease

Researchers in Seoul are beginning to unravel this mystery. Writing in mSystems, a team led by Han-Na Kim, Ph.D., at the Samsung Advanced Institute for Health Sciences and Technology at Sungkyunkwan University, examined how gut microbes interact with the cardiovascular system. "We've gone beyond identifying 'which bacteria live there' to uncovering what they actually do in the heart-gut connection," Kim explained.

The team analyzed fecal samples from 14 people with CAD and compared them to samples from 28 healthy participants using metagenomic sequencing, a powerful technique that identifies all the DNA within a sample. This approach allowed them to reconstruct the genetic makeup of individual microbes. From this analysis, the researchers identified 15 bacterial species linked to CAD and mapped the pathways that connect these microbes to the severity of the disease.

Inflammation, Imbalance, and Microbial Shifts

According to Kim, "Our high-resolution metagenomic map shows a dramatic functional shift toward inflammation and metabolic imbalance, a loss of protective short-chain fatty acid producers, such as Faecalibacterium prausnitzii, and an overactivation of pathways, such as the urea cycle, linked to disease severity."

The findings suggest that the gut ecosystem in people with CAD undergoes significant changes that promote inflammation and disrupt normal metabolic processes. These shifts may help explain why the gut microbiome plays such a strong role in cardiovascular disease.

When "Good" Bacteria Turn Harmful

Surprisingly, the study also showed that bacteria typically seen as beneficial can sometimes become harmful. Microbes such as Akkermansia muciniphila and F. prausnitzii, often considered "friendly" species, appear to act differently depending on whether they come from a healthy or a diseased gut. This dual nature, Kim noted, highlights how context can transform even protective microbes into contributors to disease.

The results also revealed how complex it is to link specific bacteria to disease outcomes. Earlier research had reported that certain species within the family Lachnospiraceae decrease in people with CAD. Yet Kim's team found that other Lachnospiraceae species actually increase in abundance. "Lachnospiraceae may be the Dr. Jekyll and Mr. Hyde of the gut," Kim said. Some types appear beneficial, while others may worsen disease. "The big unanswered question now is which strains are the healers, and which are the troublemakers."

Toward Precision Microbial Medicine

The researchers plan to combine microbial data with genetic and metabolic information to better understand how gut microbes influence heart disease at a mechanistic level. Their long-term goal is to develop precision-based treatments that use microbial insights to prevent cardiovascular disease before it begins.

Kim emphasized that prevention is the most promising approach to lowering the global impact of heart disease. Potential strategies could include microbial therapies -- such as stool-based diagnostic screening -- or dietary interventions designed to restore beneficial bacteria or inhibit harmful pathways.

By uncovering the specific bacterial species and biological mechanisms involved, scientists are moving closer to using the gut microbiome as a powerful tool for maintaining heart health.